References
- 1. Albright F. A page out of the history of hyperparathyroidism. J Clin Endocrinol Metab 1948; 8(8): 637-57.
- 2. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99(10): 3561-3569.
- 3. Clark BL. Asymptomatic Primary Hyperparathyroidism. – In: Brandi ML (ed): Parathyroid Disorders. Focusing on Unmet Needs. Front Horm Res. Basel, Karger, 2019, vol 51, 13-22.
- 4. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013; 16(1): 33-39.
- 5. Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30(1): 3-44.
- 6. Bilezikian JP. Primary Hyperparathyroidism. J Clin Endocrinol Metab 2018; 103(11): 3993-4004.
- 7. Itani M, Middleton WD. Parathyroid Imaging. Radiol Clin North Am 2020; 58(6): 1071-1083.
- 8. Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 2018; 32(5): 593-607.
- 9. Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol 2013 1(4): 329-340.
- 10. Borissova A-M, Vlahov JD, Krivoshiev SG, et al. The prevalence of hyperparathyroidism in the Bulgarian population – Analysis of an epidemiological study by the Bulgarian Society of Endocrinology (BSE) – 2012. J Endocrinologia 2019; 24(4): 202-212.
- 11. Souberbielle JC, Cavalier E, Cormier C. How to manage an isolated elevated PTH? Ann Endocrinol (Paris) 2015; 76(2): 134-41.
- 12. Borissova AM, Shinkov A, Vlahov J, et al. Prevalence of vitamin D deficiency, insufficiency and sufficiency in Bulgarian population aged 20-80 years. Endocrinologia 2012; 17(3):122-134.
- 13. Borissova AM, Rashkov R, Boyanov M, et al. Femoral neck bone mineral density and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older. Arch Osteoporos 2011; 6: 189-95.
- 14. Borissova AM, Kovatcheva R, Ivanova RB, et al. Hyperparathyroidism – a 7-year retrospective analysis at the specialized Clinic of Thyroid and Disorders of the Bone Mineral Metabolism. Endocrinologia 2004; 9(1): 33-42.
- 15. Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res 1991; 6(Suppl. 2): S51-9; discussion S61.
- 16. Babwah F, Buch HN. Normocalcaemic primary hyperparathyroidism: a pragmatic approach. J Clin Pathol 2018; 71(4): 291-297.
- 17. Abusahmin H, Geen J, Das G. Subclinical urolithiasis in patients with asymptomatic primary hyperparathyroidism. Ther Adv Endocrinol Metab 2018; 9(11): 325-327.
- 18. Burckhardt P. Lithiase rénale dans le cadre de l’hypercalciurie idiopathique et de l’hyperparathyroïdie primitive [Renal lithiasis in idiopathic hypercalciuria and primary hyperparathyroidism]. Ann Med Interne (Paris) 1986; 137(3): 216-9.
- 19. Miller A, Mitchell JP. Hyperparathyroidism and renal calculi. Br J Urol 1952; 24(2): 91-8.
- 20. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011; 96(8): 2377-85.
- 21. Selberherr A, Hörmann M, Prager G et al. “Silent” kidney stones in “asymptomatic” primary hyperparathyroidism-a comparison of multidetector computed tomography and ultrasound. Langenbecks Arch Surg 2017; 402(2): 289-293.
- 22. Wood K, Dhital S, Chen H, Sippel RS. What is the utility of distal forearm DXA in primary hyperparathyroidism? Oncologist 2012; 17(3): 322-325.
- 23. Scattergood S, Marsden M, Kyrimi E et al. Combined ultrasound and Sestamibi scintigraphy provides accurate preoperative localization for patients with primary hyperparathyroidism. Ann R Coll Surg Engl 2019; 101(2): 97-102.
- 24. Li W, Zhu Q, Lai X et al. Value of preoperative ultrasound-guided fine-needle aspiration for localization in Tc-99m MIBI-negative primary hyperparathyroidism patients. Medicine (Baltimore) 2017; 96(49): e9051.
- 25. Ketha H, Lasho MA, Algeciras-Schimnich A. Analytical and clinical validation of parathyroid hormone (PTH) measurement in fine-needle aspiration biopsy (FNAB) washings. Clin Biochem 2016; 49(1-2): 16-21.
- 26. Kwak JY, Kim EK, Moon HJ, et al. Parathyroid incidentalomas detected on routine ultrasound-directed fine-needle aspiration biopsy in patients referred for thyroid nodules and the role of parathyroid hormone analysis in the samples. Thyroid 2009; 19(7): 743-8.
- 27. Kedarisetty S, Fundakowski C, Ramakrishnan K, Dadparvar S. Clinical value of Tc99m-MIBI SPECT/CT versus 4D-CT or US in management of patients with hyperparathyroidism. Ear Nose Throat J 2019; 98(3): 149-157.